... Skip to content
World IP Day 2026 — Recognized Innovator

David Danitz

  • Senior Vice President of Engineering
  • Pulse Biosciences, Inc

Recognized for engineering leadership across the medical device industry and for helping build the device systems behind Pulse Biosciences’ nanosecond Pulsed Field Ablation platform.

Certificate of Recognition

Top IP Innovator — Bioelectric Medicine & Tissue Ablation · 2026

Pulse Biosciences Patents (last 5 years)
0
First Filing
2014
USPTO Art Unit Focus
3794 / 3792
Role
SVP of Engineering
Presented by InspireIP

World IP Day Recognition Series · 2026

Pulse Biosciences patents, last 5 years
0
Filed in 2021 alone
0
Recognition category
0 Mech & Manufacturing
The Recognition

Engineering the device side of nanosecond pulsed field ablation

On World IP Day 2026, InspireIP recognizes David Danitz, Senior Vice President of Engineering at Pulse Biosciences, for his sustained inventor footprint in medical devices and his engineering leadership in bioelectric medicine.

The recognition is based on Pulse Biosciences’ patent activity and David’s broader inventor record. He is named on more than 75 US patents across medical device development.

At Pulse Biosciences, David leads the engineering organization behind the company’s nPulse platform. That work includes the catheters, clamps, electrodes, and delivery systems used to apply nanosecond Pulsed Field Ablation energy in cardiac and soft tissue procedures.

David’s career has moved across several demanding areas of device engineering. Before Pulse, he led R&D work in hearing technology, gynecologic ablation, surgical devices, and robotic surgery systems.

He joined Pulse Biosciences in November 2015 as VP of Engineering and now serves as Senior Vice President.

Nanosecond Pulsed Field Ablation
Atrial Fibrillation Catheters
Surgical Cardiac Clamps
Percutaneous Electrodes
Bioelectric Medicine
Soft Tissue Ablation
Patent Footprint

A portfolio shaped around delivering pulsed energy precisely where it's needed

2014–2016

Pulse Biosciences is established to commercialize Nano-Pulse Stimulation technology originating from research at Old Dominion University and the Frank Reidy Research Center. The first patent filings cover pulsed electric field generators and tissue ablation methods. David Danitz joins in November 2015 as VP of Engineering.

2017–2020

13 filings across 2020 alone as the company develops the CellFX system, its first commercial nsPFA platform. The portfolio expands across pulsed energy generation, applicators, and treatment protocols.

2021–2023

A sharp acceleration. 37 patents across three years, peaking at 17 filings in 2021. Pulse Biosciences pivots its strategic focus toward higher-impact applications: cardiac ablation for atrial fibrillation and benign thyroid nodule ablation.

2024–2025

The portfolio continues to grow across cardiac catheters, surgical clamps, percutaneous electrodes, and pulsed energy delivery systems. The company also advances first-in-human clinical work around its nPulse cardiac catheter platform.

Bioelectric Medicine & Tissue Ablation

A small-entity company filing like a much larger one

Pulse Biosciences is classified by the USPTO as a Small Entity, yet its five-year filing volume of 65 patents sits well above what is typical for clinical-stage medical device companies of its size. Much of that activity is concentrated in the mechanical and manufacturing art units that protect ablation catheter designs, surgical clamps, and pulsed energy delivery systems.

Patents, last 5 years
Peak year (2021)
Filings
USPTO entity status
Small Entity
Art unit focus
3794 / 3792
"Leading an innovation program is harder than inventing on your own. It means choosing what to file, who to credit, and where to invest, over and over, for years. The leaders we recognize on World IP Day have done that consistently, and built something that compounds."

Sam Zellner

Founder, InspireIP · Inventor · Innovation Leader

About Pulse Biosciences

Built in Hayward, advancing a new modality of energy-based medicine

Headquartered in Hayward, California, Pulse Biosciences is a clinical-stage company developing Nanosecond Pulsed Field Ablation technology.

Its nPulse platform is being developed for cardiac and soft tissue ablation. In cardiac electrophysiology, the company is developing catheter-based technology for atrial fibrillation treatment. In cardiac surgery, its clamp technology is designed to create continuous ablation lines during surgical procedures.

Pulse is also studying percutaneous electrode technology for benign thyroid nodules.

The company’s patent activity supports the device systems behind this platform, including ablation catheters, surgical clamps, electrodes, generators, and pulsed energy delivery methods.

IP Day 2027

Know an IP innovator who deserves recognition?

Each year we recognize the inventors and IP leaders behind the portfolios that protect what their companies create. That includes founder-inventors whose contributions often go unmarked. Nominate someone for next year’s list.

Subscribe to Trust Center Updates

Subscribe to get notifications about important update to InspireIP's compliance journey.
By signing up for email notifications you agree to the privacy policy.

InspireIP has restricted access for 'System Acquisition and Development Lifecycle Policy'. We need your work email to validate OR request your access to this item.